Compare WOLF & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WOLF | EVO |
|---|---|---|
| Founded | 1987 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.1B |
| IPO Year | 2025 | N/A |
| Metric | WOLF | EVO |
|---|---|---|
| Price | $58.23 | $3.06 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $14.33 | $7.00 |
| AVG Volume (30 Days) | ★ 10.0M | 47.1K |
| Earning Date | 05-05-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,385,982,000.00 | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | $7.43 | $10.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.00 | N/A |
| 52 Week Low | $0.39 | $2.31 |
| 52 Week High | $80.82 | $4.42 |
| Indicator | WOLF | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 57.70 | 56.03 |
| Support Level | $15.86 | $2.88 |
| Resistance Level | $73.74 | $3.75 |
| Average True Range (ATR) | 10.79 | 0.07 |
| MACD | -0.64 | 0.01 |
| Stochastic Oscillator | 40.64 | 89.58 |
Wolfspeed Inc develops and manufactures semiconductor technologies based on silicon carbide (SiC) for power electronics applications. Its product portfolio includes SiC MOSFETs, Schottky diodes, and power modules used in power electronics applications. The company also provides reference designs, evaluation kits, and gate driver boards to support the development and integration of its SiC products across industries such as electric vehicles, renewable energy, and industrial systems.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.